Costs and Consequences of Additional Chest X-Ray in a Tuberculosis Prevention Program in Botswana
- 15 April 2011
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 183 (8) , 1103-1111
Abstract
Rationale: Isoniazid preventive therapy is effective in reducing the risk of tuberculosis (TB) in persons living with HIV (PLWH); however, screening must exclude TB disease before initiating therapy. Symptom screening alone may be insufficient to exclude TB disease in PLWH because some PLWH with TB disease have no symptoms. The addition of chest radiography (CXR) may improve disease detection. Objectives: The objective of the present analysis was to compare the costs and effects of the addition of CXR to the symptom screening process against the costs and effects of symptom screening alone. Methods: Using data from Botswana, a decision analytic model was used to compare a “Symptom only” policy against a “Symptom+CXR” policy. The outcomes of interest were cost, death, and isoniazid- and multidrug-resistant TB in a hypothetical cohort of 10,000 PLWH. Measurements and Main Results: The Symptom+CXR policy prevented 16 isoniazid- and 0.3 multidrug-resistant TB cases; however, because of attrition from the screening process, there were 98 excess cases of TB, 15 excess deaths, and an additional cost of U.S. $127,100. The Symptom+CXR policy reduced deaths only if attrition was close to zero; however, to eliminate attrition the cost would be U.S. $2.8 million per death averted. These findings did not change in best- and worst-case scenario analyses. Conclusions: In Botswana, a policy with symptom screening only preceding isoniazid-preventive therapy initiation prevents more TB and TB-related deaths, and uses fewer resources, than a policy that uses both CXR and symptom screening.Keywords
This publication has 44 references indexed in Scilit:
- Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohortAIDS, 2009
- The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, BrazilAIDS, 2007
- HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect StormThe Journal of Infectious Diseases, 2007
- Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa2006
- How Soon after Infection with HIV Does the Risk of Tuberculosis Start to Increase? A Retrospective Cohort Study in South African Gold MinersThe Journal of Infectious Diseases, 2005
- Treatment of latent tuberculosis infection in HIV infected persons2004
- A Review of Efficacy Studies of 6-Month Short-Course Therapy for Tuberculosis among Patients Infected with Human Immunodeficiency Virus: Differences in Study OutcomesClinical Infectious Diseases, 2001
- Molecular Epidemiology of Tuberculosis in the Netherlands: A Nationwide Study from 1993 through 1997The Journal of Infectious Diseases, 1999
- Site of disease and opportunistic infection predict survival in HIV-associated tuberculosisAIDS, 1997
- The Clinical Significance of Positive Cultures and of Isoniazid-resistant Tubercle Bacilli during the Treatment of Pulmonary Tuberculosis: Report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research CouncilThorax, 1955